RxDoctor Payments Data

Samantha Works, NP

Psychiatric/Mental Health · New York, NYNPI 1962884916

Payments from drug & device makers

$9,154in general payments, 2019–2025

Across 508 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$783
  • Neurocrine Biosciences, Inc.$671
  • Alkermes, Inc.$660
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$9,146100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,154 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$12,317
Medicare patients
26
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify AsimtufiiAripiprazole14$81,317
VraylarCariprazine Hcl14$20,502
Lurasidone Hcl11$3,935
Aripiprazole53$1,863
Duloxetine Hcl61$965
Clonazepam35$424
Venlafaxine Hcl ErVenlafaxine Hcl27$345
Trazodone Hcl51$325
Donepezil Hcl12$299
Buspirone Hcl27$272
Mirtazapine28$243
Quetiapine Fumarate35$193
Gabapentin15$186
Zolpidem Tartrate20$179
Alprazolam30$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii$783$81,31714 claims
AbbVieVraylar$1,026$20,50214 claims
Almatica Pharma LLCSertraline Hcl$40$5730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →